Long-term zidovudine therapy in patients with AIDS and symptomatic and asymptomatic HIV infection.
Zidovudine is the only anti-retroviral drug approved by the FDA for treatment of HIV infection. We have examined the clinical and laboratory efficacy of this drug for 4 years in a cohort of HIV-infected patients from Wisconsin. Overall, we have found that individuals with AIDS will have at least 1 year of symptom reduction while on the drug. Those with asymptomatic HIV infection tolerate the drug and none have progressed to AIDS in the 4 years of study. Zidovudine is an important component in the treatment of HIV infection.
University of Wisconsin Hospital and Clinics, Madison.
S
S
Ebert
K
K
Gockel
S
S
Horowitz
P
P
Weber
B
B
Vogelman
F
F
Graziano
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology; D000328:Adult; D015496:CD4-Positive T-Lymphocytes; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use*; D001613:beta 2-Microglobulin / Q000032:analysis
D001613:beta 2-Microglobulin; D015215:Zidovudine